Michael Gerisch
Overview
Explore the profile of Michael Gerisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frechen S, Ince I, Dallmann A, Gerisch M, Jungmann N, Becker C, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Oct;
13(1):79-92.
PMID: 37794724
Vericiguat (Verquvo; US: Merck, other countries: Bayer) is a novel drug for the treatment of chronic heart failure. Preclinical studies have demonstrated that the primary route of metabolism for vericiguat...
2.
Schulz S, Lang D, Schmuck G, Gerisch M, Bairlein M, Fricke R, et al.
Curr Drug Metab
. 2023 Aug;
24(8):599-610.
PMID: 37592798
Background: Nifurtimox is an effective treatment for patients with Chagas disease, but knowledge of its biotransformation and excretion is limited. Objective: This study aimed to better understand the fate of...
3.
Piel I, Engelen A, Lang D, Schulz S, Gerisch M, Brase C, et al.
Eur J Drug Metab Pharmacokinet
. 2023 Jun;
48(4):411-425.
PMID: 37365440
Background And Objectives: Current anticoagulants pose an increased risk of bleeding. The development of drugs targeting factor XIa, like asundexian, may provide a safer treatment option. A human mass‑balance study...
4.
Janssen W, Schwarz T, Butehorn U, Steinke W, Sandmann S, Lang D, et al.
Xenobiotica
. 2022 May;
52(5):453-462.
PMID: 35616579
Vericiguat is a soluble guanylate cyclase stimulator. The pharmacokinetics, absorption, metabolism, and excretion properties of vericiguat in rats and dogs and the distribution in rats are reported. [C]-labelled vericiguat was...
5.
Nelissen E, Possemis N, van Goethem N, Schepers M, Mulder-Jongen D, Dietz L, et al.
Sci Rep
. 2022 Mar;
12(1):3589.
PMID: 35246566
Soluble guanylate cyclase (sGC) requires a heme-group bound in order to produce cGMP, a second messenger involved in memory formation, while heme-free sGC is inactive. Two compound classes can increase...
6.
Wendl T, Frechen S, Gerisch M, Heinig R, Eissing T
CPT Pharmacometrics Syst Pharmacol
. 2021 Nov;
11(2):199-211.
PMID: 34783193
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist that recently demonstrated its efficacy to delay chronic kidney disease (CKD) progression and reduce cardiovascular events in patients with CKD and type...
7.
Nelissen E, Argyrousi E, van Goethem N, Zhao F, Hines C, Swaminath G, et al.
Biomedicines
. 2021 Aug;
9(8).
PMID: 34440254
Vascular cognitive impairment (VCI) is characterized by impairments in cerebral blood flow (CBF), endothelial function and blood-brain barrier (BBB) integrity. These processes are all physiologically regulated by the nitric oxide...
8.
Hahn M, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer K, et al.
J Med Chem
. 2021 Apr;
64(9):5323-5344.
PMID: 33872507
Herein we describe the discovery, mode of action, and preclinical characterization of the soluble guanylate cyclase (sGC) activator runcaciguat. The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is...
9.
van der Mey D, Gerisch M, Jungmann N, Kaiser A, Yoshikawa K, Schulz S, et al.
Basic Clin Pharmacol Toxicol
. 2020 Nov;
128(3):511-524.
PMID: 33232579
Molidustat is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl-hydroxylase enhancing the erythropoietin (EPO) response to HIF; it is in clinical development for the treatment of anaemia related to chronic...
10.
Boettcher M, Gerisch M, Lobmeyer M, Besche N, Thomas D, Gerrits M, et al.
Clin Pharmacokinet
. 2020 May;
59(11):1407-1418.
PMID: 32458378
Background: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). Patients with heart failure often require polypharmacy because...